AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco By Bhanvi Satija and Siddhi Mahatole
Nov 19 (Reuters) - AbbVie ABBV.N agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies.
Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb BMY.N, Pfizer PFE.N and Merck MRK.N.
In January, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors.
Disco will receive $40 million upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors. It will also be eligible for tiered royalties on worldwide net sales.
The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue.
Disco CEO Mark Manfredi said his company will be responsible for the research and discovery. AbbVie will have the right to exclusively license selected programs for further development.
"(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," said Manfredi.
The deal is at a very early stage. Disco did not disclose how many programs could be covered or when any could enter clinical development, and AbbVie's license option applies only after Disco completes specified research.
Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer, and Manfredi said the company will select a development candidate in the second half of next year.
Other recent bispecific deals include Bristol Myers Squibb's up to $11.1 billion partnership with BioNTech 22UAy.DE, Takeda's 4502.T multibillion-dollar deal with China's Innovent 1801.HK and UCB's UCB.BR $2.2 billion acquisition of Candid Therapeutics.
(Reporting by Siddhi Mahatole in Bengaluru and Bhanvi Satija in London; Editing by Sahal Muhammed)
Recent news on Bristol-Myers Squibb
See all newsEvotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
Brief: Sichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibb